Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

mtRTK inhibitor WM-S1-030

An orally bioavailable inhibitor of mutant receptor tyrosine kinase (mtRTK; pTyr-mtRTK), with potential antineoplastic activity. Upon oral administration, mtRTK inhibitor WM-S1-030 targets and binds to mtRTK, thereby inhibiting mtRTK-mediated signaling pathways. This inhibits proliferation of tumor cells expressing mtRTK.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:mutant receptor tyrosine kinase inhibitor WM-S1-030
Code name:WM-S1 030
WM-S1-030
WM-S1030
WMBIO
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search